{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-25-001844","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.550061+00:00","generated_at":"2026-05-24T05:38:25.091203+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CorMedix Q4 2024 net revenue $31.2M, first profitable quarter; H1 2025 guidance $50-60M","bullets":["Q4 2024 net revenue $31.2M; net income $13.5M ($0.22/diluted share); adjusted EBITDA $15.3M.","Full year 2024 net revenue $43.5M; net loss narrowed to $17.9M ($0.30/share) from $46.3M in 2023.","Preliminary H1 2025 revenue guidance $50-60M (Q1 >$33M); cash operating expense guidance $72-78M reaffirmed.","Cash and short-term investments $51.7M at Dec 31, 2024; expects >$75M at Q1 2025 end.","Inpatient sales team with Syneos Health nearly complete; Phase 3 DefenCath TPN study to start Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-25-001844","json":"https://secwatch.observer/filing/0001013762-25-001844.json","markdown":"https://secwatch.observer/filing/0001013762-25-001844.md","text":"https://secwatch.observer/filing/0001013762-25-001844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000101376225001844/0001013762-25-001844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000101376225001844/ea0235520-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:38:25.091203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}